Literature DB >> 7273594

Digoxin-verapamil interaction.

K E Pedersen, A Dorph-Pedersen, S Hvidt, N A Klitgaard, F Nielsen-Kudsk.   

Abstract

To explore a possible interaction between digoxin and verapamil, a single-dose kinetic study of digoxin was performed and then repeated after 10 days of verapamil treatment in eight healthy subjects. Verapamil diminished the apparent central distribution volume of digoxin from 0.83 +/- 0.25 to 0.64 +2- 0.17 l/kg (P less than 0.05) and reduced total body clearance of digoxin from 3.28 +/- 0.58 to 2.15 +/- 0.66 ml/min/kg (P less than 0.001) by impairing both renal and extrarenal clearance. Biological digoxin half-life rose from 38.6 +/- 8.5 to 50.5 +/- 8.3 hr (P less than 0.005). Reduction of renal clearance of digoxin may be due to inhibition of tubular secretion. The underlying mechanisms of extrarenal interaction are not known, but impaired hepatic degradation of digoxin induced by verapamil should be considered.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273594     DOI: 10.1038/clpt.1981.165

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  38 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Drug treatment of cardiac failure.

Authors:  M R Achong; C R Kumana
Journal:  Can Fam Physician       Date:  1982-01       Impact factor: 3.275

Review 4.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

5.  Interaction study of fenoldopam--digoxin in congestive heart failure.

Authors:  E Strocchi; F Tartagni; P L Malini; G Valtancoli; E Ambrosioni; F Pasinelli; E Riva; L M Fuccella
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers.

Authors:  G I Adebayo; A Akintonwa; A F Mabadeje
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  Digoxin-diltiazem interaction: a pharmacokinetic evaluation.

Authors:  W N Jones; K B Kern; J P Rindone; M Mayersohn; M Bliss; S Goldman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Verapamil-induced changes in digoxin kinetics in cirrhosis.

Authors:  I Maragno; C Gianotti; P F Tropeano; V Rodighiero; R M Gaion; C Paleari; R Prandoni; L Menozzi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 10.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.